Belite Bio Analyst Price Targets

Wall Street analyst price targets and consensus rating for Belite Bio (BLTE).

Price Target Range — 12 Quarters

Analyst Consensus — 8 Analysts

8Buy

Consensus RatingBuy# Analysts8Avg. Consensus PT$197Upside to Avg. PT+15.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 9, 2026	Mizuho	Graig Suvannavejh	PT Raise	Outperform	$220→$234
Sep 8, 2026	HC Wainwright & Co.	Yi Chen	PT Raise	Buy	$214→$245
Sep 4, 2026	Canaccord Genuity	Whitney Ijem	Initiate	Buy	$303
Aug 14, 2026	Morgan Stanley	Judah Frommer	PT Raise	Overweight	$201→$206
Aug 14, 2026	Cantor Fitzgerald	Steve Seedhouse	PT Raise	Overweight	$266→$270
Aug 12, 2026	HC Wainwright & Co.	Yi Chen	PT Raise	Buy	$200→$214
Jun 15, 2026	HC Wainwright & Co.	Yi Chen	Maintained	Buy	$200
May 26, 2026	Mizuho	Graig Suvannavejh	PT Cut	Outperform	$223→$215
May 21, 2026	HC Wainwright & Co.	Yi Chen	Maintained	Buy	$200
Apr 22, 2026	HC Wainwright & Co.	Yi Chen	Maintained	Buy	$200
Apr 13, 2026	HC Wainwright & Co.	Yi Chen	Maintained	Buy	$200
Mar 3, 2026	HC Wainwright & Co.	Yi Chen	PT Raise	Buy	$185→$200
Mar 3, 2026	Morgan Stanley	Judah Frommer	PT Raise	Overweight	$191→$201
Mar 3, 2026	Cantor Fitzgerald	Steve Seedhouse	PT Raise	Overweight	$200→$266
Jan 28, 2026	HC Wainwright & Co.	Yi Chen	Maintained	Buy	$185
Jan 26, 2026	B of A Securities	Tazeen Ahmad	Initiate	Buy	$195
Jan 6, 2026	Morgan Stanley	Judah Frommer	Initiate	Overweight	$191
Dec 2, 2025	Mizuho	Graig Suvannavejh	Upgrade	Neutral→Outperform	$105→$194
Dec 1, 2025	HC Wainwright & Co.	Yi Chen	PT Raise	Buy	$98→$185
Nov 24, 2025	Cantor Fitzgerald	Steve Seedhouse	Assumes	Overweight	$154

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Mizuho Maintains Outperform on Belite Bio, Raises Price Target to $234

Mizuho analyst Graig Suvannavejh maintains Belite Bio (NASDAQ:BLTE) with a Outperform and raises the price target from $220 to $234.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Belite Bio, Raises Price Target to $245

HC Wainwright & Co. analyst Yi Chen maintains Belite Bio (NASDAQ:BLTE) with a Buy and raises the price target from $214 to $245.

Benzinga Newsdesk

Why Is Belite Bio Stock Soaring Friday?

Canaccord Genuity initiates Belite Bio (BLTE) with a Buy and $303 target on FDA Priority Review for tinlarebant.

Vandana Singh

This PulteGroup Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday

Analysts initiated coverage: Hold on Lennar, Buys on Belite Bio, PulteGroup.

Avi Kapoor

PRO
Canaccord Genuity Initiates Coverage On Belite Bio with Buy Rating, Announces Price Target of $303

Canaccord Genuity analyst Whitney Ijem initiates coverage on Belite Bio (NASDAQ:BLTE) with a Buy rating and announces Price Target of $303.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Belite Bio, Raises Price Target to $206

Morgan Stanley analyst Judah Frommer maintains Belite Bio (NASDAQ:BLTE) with a Overweight and raises the price target from $201 to $206.

Benzinga Newsdesk

Belite Bio Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Belite Bio Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Mizuho Maintains Outperform on Belite Bio, Raises Price Target to $234

PRO
HC Wainwright & Co. Maintains Buy on Belite Bio, Raises Price Target to $245

Why Is Belite Bio Stock Soaring Friday?

This PulteGroup Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday

PRO
Canaccord Genuity Initiates Coverage On Belite Bio with Buy Rating, Announces Price Target of $303

PRO
Morgan Stanley Maintains Overweight on Belite Bio, Raises Price Target to $206

People Also Watch

People Also Watch

Belite Bio Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Belite Bio Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROMizuho Maintains Outperform on Belite Bio, Raises Price Target to $234

PROHC Wainwright & Co. Maintains Buy on Belite Bio, Raises Price Target to $245

Why Is Belite Bio Stock Soaring Friday?

This PulteGroup Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday

PROCanaccord Genuity Initiates Coverage On Belite Bio with Buy Rating, Announces Price Target of $303

PROMorgan Stanley Maintains Overweight on Belite Bio, Raises Price Target to $206

People Also Watch

People Also Watch

PRO
Mizuho Maintains Outperform on Belite Bio, Raises Price Target to $234

PRO
HC Wainwright & Co. Maintains Buy on Belite Bio, Raises Price Target to $245

PRO
Canaccord Genuity Initiates Coverage On Belite Bio with Buy Rating, Announces Price Target of $303

PRO
Morgan Stanley Maintains Overweight on Belite Bio, Raises Price Target to $206